{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:49:04Z","timestamp":1791776944025,"version":"4.3.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaci.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:19:08Z","timestamp":1742303948000},"page":"1411-1419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical and mechanistic advancements in aspirin exacerbated respiratory disease"],"prefix":"10.1016","volume":"155","author":[{"given":"Shabnam","family":"Elahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-6610","authenticated-orcid":false,"given":"Whitney W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.03.006_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib4","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jaip.2024.07.013","article-title":"Updates on the natural history and clinical characteristics of NSAID-ERD","volume":"12","author":"Jermihov","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaip.2016.05.016","article-title":"Aspirin-exacerbated respiratory disease: not always \"adult-onset\"","volume":"4","author":"Tuttle","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib6","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.jaip.2022.05.016","article-title":"Pediatric-onset aspirin-exacerbated respiratory disease: clinical characteristics, prevalence, and response to dupilumab","volume":"10","author":"Bensko","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1034\/j.1399-3003.2000.016003432.x","article-title":"European Network on Aspirin-Induced Asthma","volume":"16","author":"Szczeklik","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.03.006_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib9","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1016\/j.jaip.2023.07.035","article-title":"Sex, ethnicity, body mass index, and environmental exposures associated with NSAID-exacerbated respiratory disease symptom sequence","volume":"11","author":"Dages","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147326","article-title":"Aspirin-exacerbated respiratory disease polymorphisms; a review study","volume":"870","author":"Fathollahpour","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.jaci.2025.03.006_bib11","article-title":"Aspirin-exacerbated respiratory disease is associated with variants in filaggrin, epithelial integrity, and cellular interactions","volume":"3","author":"Jerschow","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaci.2025.03.006_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2016.06.010","article-title":"Genetic and epigenetic components of aspirin-exacerbated respiratory disease","volume":"36","author":"Dahlin","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2025.03.006_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.anai.2011.09.022","article-title":"Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease","volume":"108","author":"Chang","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00462-2021","article-title":"NSAID-exacerbated respiratory disease: a population study","volume":"8","author":"Andersen","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2025.03.006_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","article-title":"The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy","volume":"147","author":"Stevens","year":"2021","journal-title":"Asthma & Immunology. J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/cea.14157","article-title":"Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life","volume":"52","author":"Tchekmedyian","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00405-016-4366-x","article-title":"Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study","volume":"274","author":"Gudziol","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaci.2025.03.006_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/alr.22249","article-title":"Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms","volume":"9","author":"Morse","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.006_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/alr.22242","article-title":"Impaired eating-related quality of life in chronic rhinosinusitis","volume":"9","author":"Rowan","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaci.2025.03.006_bib20","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2024.06.044","article-title":"The burden of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease: interplay between quality of life and economic implications","volume":"12","author":"Rowan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.03.006_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.03.006_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib31","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib32","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib33","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1016\/j.jaip.2024.09.012","article-title":"Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics","volume":"12","author":"Bobolea","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/all.15982","article-title":"EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care","volume":"79","author":"Hellings","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib35","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.jaip.2024.09.021","article-title":"Efficacy of biologics in NSAID-ERD: united airways from the nose to the bronchi","volume":"12","author":"Buchheit","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaci.2025.03.006_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/ACI.0000000000001051","article-title":"New insights into the mechanisms of aspirin-exacerbated respiratory disease","volume":"25","author":"Laidlaw","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib39","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaci.2012.05.052","article-title":"Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4","volume":"130","author":"Soyka","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib40","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jaci.2023.01.030","article-title":"Type 2 inflammation drives an airway basal stem cell program through insulin receptor substrate signaling","volume":"151","author":"Wang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2024.04.020","article-title":"IL-4Ralpha signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease","volume":"154","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaci.2015.01.043","article-title":"Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease","volume":"136","author":"Pothoven","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib43","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. a randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib46","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2025.03.006_bib47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaci.2015.05.041","article-title":"Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Mitsui","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2018.06.001","article-title":"A trial of type 12 purinergic (P2Y(12)) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease","volume":"143","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib49","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2023.03.030","article-title":"Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease","volume":"152","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib50","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.2300102","article-title":"Glucagon-like peptide-1 receptor pathway attenuates platelet activation in aspirin-exacerbated respiratory disease","volume":"211","author":"Foer","year":"2023","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib51","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/1744666X.2021.1971973","article-title":"The GLP-1 receptor in airway inflammation in asthma: a promising novel target?","volume":"17","author":"Wu","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/ACI.0000000000000498","article-title":"Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells","volume":"19","author":"Rusznak","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1165\/rcmb.2014-0486OC","article-title":"Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease","volume":"54","author":"Cahill","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2025.03.006_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaci.2015.09.028","article-title":"Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta\/IL-1 type I receptor\/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Machado-Carvalho","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib55","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4193\/Rhino15.207","article-title":"Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling","volume":"54","author":"Machado-Carvalho","year":"2016","journal-title":"Rhinology"},{"key":"10.1016\/j.jaci.2025.03.006_bib56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2005.10.037","article-title":"Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells","volume":"117","author":"Ying","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib57","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaci.2012.02.007","article-title":"Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma","volume":"129","author":"Corrigan","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/ajrccm.153.2.8564100","article-title":"Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma","volume":"153","author":"Sestini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib60","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cea.14158","article-title":"Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: a randomized controlled clinical trial","volume":"52","author":"Price","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib62","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib63","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jaci.2019.06.037","article-title":"15-Lipoxygenase 1 in nasal polyps promotes CCL26\/eotaxin 3 expression through extracellular signal-regulated kinase activation","volume":"144","author":"Li","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib64","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1164\/rccm.200811-1744OC","article-title":"Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells","volume":"179","author":"Zhao","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib65","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/cea.14484","article-title":"Increased SERPINB2 potentiates 15LO1 expression via STAT6 signalling in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps","volume":"54","author":"Luo","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib66","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1046\/j.1365-2222.2002.01477.x","article-title":"Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition","volume":"32","author":"Chu","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib67","doi-asserted-by":"crossref","first-page":"14376","DOI":"10.1073\/pnas.1921618117","article-title":"PEBP1 acts as a rheostat between prosurvival autophagy and ferroptotic death in asthmatic epithelial cells","volume":"117","author":"Zhao","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.03.006_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151685","article-title":"15LO1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation","volume":"132","author":"Nagasaki","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.03.006_bib69","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2020.04.031","article-title":"Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41588-018-0314-6","article-title":"A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis","volume":"51","author":"Kristjansson","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2025.03.006_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2024.106886","article-title":"Mucosal LTE(4), PGD(2) and 15(S)-HETE as potential prognostic markers for polyp recurrence in chronic rhinosinusitis","volume":"174","author":"Nordstrom","year":"2024","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaci.2025.03.006_bib72","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaip.2016.11.021","article-title":"Plasma 15-hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease","volume":"5","author":"Jerschow","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib73","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jaci.2023.06.028","article-title":"Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD","volume":"152","author":"Badrani","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib74","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/cea.13886","article-title":"Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease","volume":"51","author":"Tyrak","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib75","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/all.16281","article-title":"Aspirin hypersensitivity diagnostic index (AHDI): in\u00a0vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE(4) excretion","volume":"80","author":"Mastalerz","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib76","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaip.2024.01.029","article-title":"Absolute eosinophil counts in aspirin-exacerbated respiratory disease are distinctly elevated and correlate inversely with respiratory function","volume":"12","author":"Supron","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib77","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.03.006_bib78","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/lary.21969","article-title":"Evidence for distinct histologic profile of nasal polyps with and without eosinophilia","volume":"121","author":"Payne","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.006_bib79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2021.02.045","article-title":"Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis","volume":"148","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2012.02.046","article-title":"Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps","volume":"130","author":"Takabayashi","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/iid3.161","article-title":"Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps","volume":"5","author":"Poposki","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaci.2025.03.006_bib83","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.03.006_bib84","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jaip.2022.03.021","article-title":"Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease","volume":"10","author":"Corey","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib85","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven il-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib86","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jaci.2013.05.042","article-title":"Regional differences in the expression of innate host defense molecules in sinonasal mucosa","volume":"132","author":"Seshadri","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib87","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaci.2016.06.063","article-title":"Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois","volume":"139","author":"Tan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib88","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jaci.2016.10.039","article-title":"Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease","volume":"139","author":"Pothoven","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.01.043","article-title":"Chronic\u00a0rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression","volume":"131","author":"Hulse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib90","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5Ralpha marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib91","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2025.03.006_bib92","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177729","article-title":"Increased autoreactivity and maturity of EBI2+ antibody-secreting cells from nasal polyps","volume":"9","author":"Bai","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.03.006_bib94","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2023.10.011","article-title":"Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease","volume":"153","author":"Sohail","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib95","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1111\/all.16218","article-title":"Human nasal epithelial cells express IL-5Ralpha but not the co-receptor CSF2RB and do not signal to IL-5","volume":"79","author":"Sohail","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib96","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jaci.2020.04.064","article-title":"Inflammatory macrophage memory in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"147","author":"Haimerl","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib97","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/all.16117","article-title":"Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID-exacerbated respiratory disease","volume":"79","author":"Hartung","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib98","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.jaip.2024.07.035","article-title":"Understanding Inflammatory Heterogeneity in NSAID-exacerbated respiratory disease","volume":"12","author":"Turner","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2025.03.006_bib99","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib100","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2020.08.007","article-title":"Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease","volume":"147","author":"Jakiela","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib101","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaci.2022.10.029","article-title":"Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease","volume":"151","author":"Jakiela","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12235","article-title":"Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease","volume":"13","author":"Mastalerz","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4168\/aair.2015.7.5.421","article-title":"Chronic rhinosinusitis and the coagulation system","volume":"7","author":"Kim","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2025.03.006_bib104","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaci.2020.01.027","article-title":"Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin","volume":"145","author":"Takabayashi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaci.2013.02.003","article-title":"Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps","volume":"132","author":"Takabayashi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.03.006_bib106","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/all.13677","article-title":"Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"74","author":"Takabayashi","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2025.03.006_bib107","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jaci.2022.05.021","article-title":"Retinoic acid promotes fibrinolysis and may regulate polyp formation","volume":"150","author":"Sakashita","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925002933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925002933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:32:43Z","timestamp":1777264363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925002933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0091674925002933"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.03.006","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and mechanistic advancements in aspirin exacerbated respiratory disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}